Why the study?
Does the presentation of neuroleptic malignant syndrome differ when caused by atypical antipsychotics compared to typical antipsychotics?
Does the presentation of neuroleptic malignant syndrome differ when caused by atypical antipsychotics compared to typical antipsychotics?
Answers are grounded in this paper and cite their sources.
Clinicians should be aware that NMS associated with atypical antipsychotics may have an atypical presentation with less frequent fever and rigidity.
The neuroleptic malignant syndrome (NMS) is an idiopathic, life-threatening reaction to antipsychotic medication. NMS was traditionally attributed to potent dopamine antagonism of typical antipsychotics, but cases of NMS have now been reported for each of the newer antipsychotics. When NMS is caused by a newer, atypical antipsychotic the presentation differs somewhat; fever, rigidity, and, possibly, death may be less frequent. Diagnostic features, predisposing factors, and treatment are discussed, as is the important matter of reinstituting antipsychotic treatment.
No takes yet. Share an insight, caveat, or question.
Guzofski et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: